1. Home
  2. SCLXW vs GAINI Comparison

SCLXW vs GAINI Comparison

Compare SCLXW & GAINI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.18

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

GAINI

Gladstone Investment Corporation 7.875% Notes due 2030

N/A

Current Price

$25.86

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
SCLXW
GAINI
Founded
N/A
N/A
Country
United States
United States
Employees
30
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLXW
GAINI
Price
$0.18
$25.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
N/A
Earning Date
03-07-2025
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,152,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
22.02
N/A
52 Week Low
$0.18
N/A
52 Week High
$0.18
N/A

Technical Indicators

Market Signals
Indicator
SCLXW
GAINI
Relative Strength Index (RSI) 55.73 56.93
Support Level $0.07 $25.73
Resistance Level $0.18 $25.87
Average True Range (ATR) 0.03 0.08
MACD 0.01 -0.00
Stochastic Oscillator 91.84 87.50

Price Performance

Historical Comparison
SCLXW
GAINI

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: